Bavarian Nordic's Headquarters: Where Innovation Meets Precision

Bavarian Nordic is a biotechnology company that develops and produces vaccines for the treatment and prevention of life-threatening diseases. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark, and Thörishaus, Switzerland. In addition to its manufacturing capabilities, Bavarian Nordic also has research and development facilities in Germany and the United States, as well as offices in Switzerland and North Carolina. The company's focus on vaccine development and global presence make it a key player in the biotechnology industry.

Headquarters in Hellerup, Denmark

Bavarian Nordic A/S is a biotechnology company that develops, manufactures, and commercialises vaccines. The company's headquarters are in Hellerup, Denmark, and it has manufacturing facilities in Kvistgård, Denmark, and Thörishaus near Bern, Switzerland. Hellerup is an affluent suburb of Copenhagen, Denmark's capital city, and is located on the coast of the Øresund Strait, which separates Denmark from Sweden. The area is known for its picturesque scenery and upscale residences, and the headquarters are strategically located to provide easy access to the rest of Denmark and beyond.

Bavarian Nordic's presence in Hellerup places it in a vibrant life sciences hub, with numerous pharmaceutical and biotechnology companies also choosing the area for their operations. This clustering of life science expertise fosters a collaborative environment and provides access to a highly skilled workforce. The area is also home to leading research institutions and universities, facilitating knowledge exchange and innovation. The headquarters location is well-connected to the rest of Denmark and Europe, making it convenient for both domestic and international business operations.

The Hellerup headquarters houses Bavarian Nordic's administrative and leadership functions, bringing together key decision-makers and strategic teams. The site serves as a hub for the company's global operations, providing a central point of contact for its various facilities and offices worldwide. By basing themselves in Hellerup, Bavarian Nordic gains access to a highly educated talent pool, with Danish universities known for producing top graduates in science, technology, engineering, and mathematics (STEM) fields. This ensures that the company can recruit the best professionals to drive forward its research, development, and manufacturing endeavours.

In addition to its headquarters, Bavarian Nordic also maintains research and development facilities in Martinsried, Germany, and San Diego, California, as well as offices in Zug, Switzerland, and Morrisville, North Carolina. The company's global presence and diverse locations enable it to tap into different markets, access specialised talent, and respond effectively to the diverse needs of its international customer base. By centralising key functions in Hellerup, Denmark, Bavarian Nordic positions itself at the heart of a thriving life sciences ecosystem, benefiting from the country's strong reputation for pharmaceutical innovation and its supportive business environment.

Manufacturing facilities in Denmark and Switzerland

Bavarian Nordic is a biotechnology company that develops and manufactures vaccines for the treatment and prevention of life-threatening diseases. The company is headquartered in Hellerup, Denmark, and has manufacturing facilities in two locations: Kvistgård, Denmark, and Thörishaus, Switzerland.

The Kvistgård facility is located in the Hovedstaden region of Denmark and is responsible for the production of vaccines, playing a crucial role in the company's commitment to providing reliable manufacturing and supply of vaccines globally.

The Thörishaus manufacturing facility, situated near Bern, Switzerland, is an integral part of Bavarian Nordic's global operations. This site was strategically chosen to facilitate the distribution of vaccines across Europe and beyond, leveraging Switzerland's strong life sciences industry and favourable business environment.

Both manufacturing facilities adhere to stringent international standards, ensuring the highest quality and safety in the production of vaccines. The sites are equipped with state-of-the-art technology and a dedicated team of experts who work tirelessly to meet the company's goals and address global health challenges.

In addition to its manufacturing capabilities, Bavarian Nordic also boasts research and development facilities in Martinsried, Germany, and San Diego, California, as well as offices in various locations, including Zug, Switzerland, and Morrisville, North Carolina. The company's international presence and collaboration with partners worldwide reflect its commitment to addressing global health risks and improving access to innovative vaccines.

Research and development facilities in Germany and the US

Bavarian Nordic is an industrial biotechnology company that develops and produces vaccines for the treatment and prevention of life-threatening diseases. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark, and Thörishaus, Switzerland.

Bavarian Nordic has established a solid presence in Germany and the United States, with research and development facilities in both countries, playing a crucial role in the company's commitment to creating innovative vaccines.

In Germany, the company's research and development facility is strategically located in Martinsried. This site serves as a hub for a dedicated team of scientists and researchers who leverage cutting-edge technologies to advance the company's vaccine development efforts. The Martinsried facility is instrumental in driving forward Bavarian Nordic's pipeline of vaccine candidates, ensuring they remain at the forefront of infectious disease prevention.

In the United States, Bavarian Nordic has established two key research and development sites, one in San Diego, California, and the other in Morrisville, North Carolina. The San Diego facility, nestled in the heart of a vibrant biotechnology community, fosters collaboration and innovation. The site attracts top talent from across the country, bringing together experts in vaccine research and development. Meanwhile, the Morrisville facility, situated in the Research Triangle region of North Carolina, leverages the area's rich history of scientific advancements. This facility contributes significantly to the company's research endeavours, particularly in the realm of vaccine development and testing methodologies.

The German and US research and development facilities are integral to Bavarian Nordic's success, enabling the company to remain agile in addressing emerging global health challenges. These strategic locations facilitate access to cutting-edge technologies, top talent, and innovative collaborations, ultimately contributing to the company's ability to develop and deliver life-saving vaccines worldwide.

Copenhagen stock exchange listing

Bavarian Nordic A/S is a biotechnology company headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark, and Thörishaus, Switzerland. The company is listed on the Copenhagen Stock Exchange (CSE), also known as Nasdaq Copenhagen, under the ticker symbol BAVA.CO.

The CSE is Denmark's official market for securities and was founded in 1808. It became a limited company in 1996 and joined the Nasdaq OMX group in 2005 as part of its Nasdaq Nordic division. Today, it is part of the Nasdaq Nordic group, which includes the exchanges of Copenhagen, Stockholm, Helsinki, and Iceland.

The process of listing on the CSE/Nasdaq Copenhagen involves several steps and can be demanding for the company's management. The company must first ensure it meets the requirements for listing, which are in line with the Danish Capital Markets Act and EU laws for market abuse and transparency. The company must also prepare the necessary documentation, including accounts for the past three fiscal years, registered articles of association, proof of registration with the Danish Business Authority, and detailed proof of fulfilling the listing requirements.

Once the company and its advisors have prepared the documentation, the actual process of admission to trading begins, where the company must be approved by Nasdaq Copenhagen. This includes submitting the documentation to the exchange for assessment, with a focus on the company's description of how it fulfils each listing requirement. The exchange will then work with the Danish FSA to approve the company's admission regarding the prospectus. Finally, when the exchange finds that the company fulfils all the requirements, formal approval for admission to trading will be granted based on the company's formal application.

Focus on biodefence, cancer and infectious diseases

Bavarian Nordic is a biotechnology company with a core focus on the development, manufacturing, and commercialisation of vaccines. The company's clinical pipeline targets cancer and infectious diseases, with a particular emphasis on biodefence.

Cancer

Bavarian Nordic has a dedicated cancer research unit in California, USA, known as BN ImmunoTherapeutics, Inc. The unit is led by Division President Cancer Vaccines, Reiner Laus, who was appointed in 2010. The main short-term strategic objectives of the cancer division include driving PROSTVAC(TM) to market through partnerships, broadening the portfolio through acquisitions, and developing new cancer targets. PROSTVAC(TM) is a therapeutic vaccine for advanced prostate cancer, developed in collaboration with the National Cancer Institute.

Infectious Diseases

The company's infectious disease division is led by Division President Infectious Diseases, Paul Chaplin. The division focuses on the continued delivery of IMVAMUNE(R) under a contract with the US government, as well as securing new orders and developing new late-stage vaccine candidates for infectious diseases beyond biodefence.

Bavarian Nordic's work in this area includes the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases, in collaboration with the NIAID and Janssen Pharmaceuticals. The vaccine was first deployed in 2015 to help contain an outbreak in West Africa and was approved for medical use in the European Union in July 2020.

Biodefence

Bavarian Nordic's work in biodefence includes the development of vaccines for smallpox and mpox (monkeypox). Their MVA-BN vaccine is a non-replicating smallpox and mpox vaccine, approved in Canada, the European Union, and the United States. The vaccine was supplied for emergency use during the 2022 mpox outbreak, with concerns raised about vaccine nationalism and hoarding. The company has also developed vaccines for rabies, tick-borne encephalitis, typhoid fever, cholera, and chikungunya.

Frequently asked questions